Addex Therapeutics Ltd (NASDAQ:ADXN) Sees Significant Drop in Short Interest

Addex Therapeutics Ltd (NASDAQ:ADXN) was the recipient of a large decrease in short interest in June. As of June 30th, there was short interest totalling 2,800 shares, a decrease of 40.4% from the June 15th total of 4,700 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 12,800 shares, the days-to-cover ratio is presently 0.2 days.

Addex Therapeutics Stock Performance

Shares of ADXN opened at $8.31 on Friday. The firm has a market capitalization of $8.81 million, a price-to-earnings ratio of -0.48 and a beta of 1.77. Addex Therapeutics has a 52 week low of $5.00 and a 52 week high of $27.90. The business’s fifty day moving average price is $8.56 and its two-hundred day moving average price is $10.63.

Addex Therapeutics (NASDAQ:ADXN) last posted its quarterly earnings results on Thursday, June 6th. The company reported ($1.37) earnings per share (EPS) for the quarter. The firm had revenue of $0.27 million during the quarter. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. As a group, research analysts forecast that Addex Therapeutics will post -11.8 EPS for the current year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.